Establishment of a non-alcoholic fatty liver disease model by high fat diet in adult zebrafish

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in recent years, but the pathogenesis is not fully understood. Therefore, it is important to establish an effective animal model for studying NAFLD.

Methods: Adult zebrafish were fed a normal diet or a high-fat diet combined with egg yolk powder for 30 days. Body mass index (BMI) was measured to determine overall obesity. Serum lipids were measured using triglyceride (TG) and total cholesterol (TC) kits. Liver lipid deposition was detected by Oil Red O staining. Liver injury was assessed by measuring glutathione aminotransferase (AST) and glutamic acid aminotransferase (ALT) levels. Reactive oxygen species (ROS) and malondialdehyde (MDA) were used to evaluate oxidative damage. The level of inflammation was assessed by qRT-PCR for pro-inflammatory factors. H&E staining was used for pathological histology. Caspase-3 immunofluorescence measured apoptosis. Physiological disruption was assessed via RNA-seq analysis of genes at the transcriptional level and validated by qRT-PCR.

Results: The high-fat diet led to significant obesity in zebrafish, with elevated BMI, hepatic TC, and TG. Severe lipid deposition in the liver was observed by ORO and H&E staining, accompanied by massive steatosis and ballooning. Serum AST and ALT levels were elevated, and significant liver damage was observed. The antioxidant system in the body was severely imbalanced. Hepatocytes showed massive apoptosis. RNA-seq results indicated that several physiological processes, including endoplasmic reticulum stress, and glucolipid metabolism, were disrupted.

Conclusion: Additional feeding of egg yolk powder to adult zebrafish for 30 consecutive days can mimic the pathology of human nonalcoholic fatty liver disease.

Keywords

ER stress / high-fat-diet / metabolism / non-alcoholic fatty liver disease / zebrafish

References

[1] Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;682:268-279.

[2] Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;247:908-922.

[3] Wang C, Hu N-H, Yu L-Y, et al. 2,3,5,4′-tetrahydroxystilbence-2-O -β-D-glucoside attenuates hepatic steatosis via IKKβ/NF-κB and Keap1-Nrf2 pathways in larval zebrafish. Biomed Pharmacother. 2020;127:110138.

[4] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;696:2672-2682.

[5] Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;715:1851-1864.

[6] Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD/NASH: targets and therapy. Pharmacol Res. 2021;167:105484.

[7] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;658:1038-1048.

[8] Engin A. Non-alcoholic fatty liver disease. Adv Exp Med Biol. 2017;960:443-467.

[9] Willebrords J, Pereira IVA, Maes M, et al. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res. 2015;59:106-125.

[10] Chen B, Zheng Y-M, Zhang J-P. Comparative study of different diets-induced NAFLD models of zebrafish. Front Endocrinol (Lausanne). 2018;9:366.

[11] García-Moreno D, Tyrkalska SD, Valera-Pérez A, Gómez-Abenza E, Pérez-Oliva AB, Mulero V. The zebrafish: a research model to understand the evolution of vertebrate immunity. Fish Shellfish Immunol. 2019;90:215-222.

[12] Wilkins BJ, Pack M. Zebrafish models of human liver development and disease. Compr Physiol. 2013;33:1213-1230.

[13] Winata CL, Dodzian J, Bialek-Wyrzykowska U. The zebrafish as a model for developmental and biomedical research in Poland and beyond. Dev Biol. 2020;4572:167-168.

[14] Ma J, Yin H, Li M, et al. A comprehensive study of high cholesterol diet-induced larval zebrafish model: a short-time screening method for non-alcoholic fatty liver disease drugs. Int J Biol Sci. 2019;155:973-983.

[15] Sun L, Ling Y, Jiang J, et al. Differential mechanisms regarding triclosan vs. bisphenol a and fluorene-9-bisphenol induced zebrafish lipid-metabolism disorders by RNA-seq. Chemosphere. 2020;251:126318.

[16] Templehof H, Moshe N, Avraham-Davidi I, et al. Zebrafish mutants provide insights into apolipoprotein B functions during embryonic development and pathological conditions. JCI Insight. 2021;6:e130399.

[17] Kanuri G, Bergheim I. In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci. 2013;146:11963-11980.

[18] Li X, Wang T-X, Huang X, et al. Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity. Liver Int. 2020;406:1378-1394.

[19] Zhong F, Zhou X, Xu J, Gao L. Rodent models of nonalcoholic fatty liver disease. Digestion. 2020;1015:522-535.

[20] Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;1303:1453-1460.

[21] Wang W, Zhao J, Gui W, et al. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol. 2018;1753:469-484.

[22] Zhou T, Chang L, Luo Y, Zhou Y, Zhang J. Mst1 inhibition attenuates non-alcoholic fatty liver disease via reversing parkin-related mitophagy. Redox Biol. 2019;21:101120.

[23] An J, Cheng L, Yang L, et al. P-hydroxybenzyl alcohol alleviates oxidative stress in a nonalcoholic fatty liver disease larval zebrafish model and a BRL-3A hepatocyte the Nrf2 pathway. Front Pharmacol. 2021;12:646239.

[24] Sapp V, Gaffney L, EauClaire SF, et al. Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition. Hepatology. 2014;605:1581-1592.

[25] An HJ, Lee YJ, Choe CP, et al. Long noncoding RNAs associated with nonalcoholic fatty liver disease in a high cholesterol diet adult zebrafish model. Sci Rep. 2021;111:23005.

[26] Zou Y, Chen Z, Sun C, et al. Exercise intervention mitigates pathological liver changes in NAFLD zebrafish by activating SIRT1/AMPK/NRF2 signaling. Int J Mol Sci. 2021;22:10940.

[27] Zhu Z, Zhang Y, Huang X, et al. Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4. Eur J Pharmacol. 2021;908:174351.

[28] Yu Q, Huo J, Zhang Y, et al. Tamoxifen-induced hepatotoxicity via lipid accumulation and inflammation in zebrafish. Chemosphere. 2020;239:124705.

[29] Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;178:484-495.

[30] Wang W, Zhu M, Xu Z, et al. Ropivacaine promotes apoptosis of hepatocellular carcinoma cells through damaging mitochondria and activating caspase-3 activity. Biol Res. 2019;521:36.

[31] Kim JY, Garcia-Carbonell R, Yamachika S, et al. ER stress drives lipogenesis and steatohepatitis via Caspase-2 activation of S1P. Cell. 2018;175:133-145.

[32] Zhang L, Zhang Z, Li C, et al. S100A11 promotes liver steatosis via FOXO1-mediated autophagy and lipogenesis. Cell Mol Gastroenterol Hepatol. 2021;113:697-724.

[33] Long J-K, Dai W, Zheng Y-W, et al. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med. 2019;251:26.

[34] Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;484:434-441.

[35] Alves-Bezerra M, Cohen DE. Triglyceride metabolism in the liver. Compr Physiol. 2017;81:1-8.

[36] Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;682:280-295.

[37] Farzanegi P, Dana A, Ebrahimpoor Z, et al. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation. Eur J Sport Sci. 2019;19:994-1003.

[38] Rives C, Fougerat A, Ellero-Simatos S, et al. Oxidative stress in NAFLD: role of nutrients and food contaminants. Biomolecules. 2020;10:1702.

[39] Paradies G, Paradies V, Ruggiero FM, et al. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;2039:14205-14218.

[40] Xiong X, Ren Y, Cui Y, Li R, Wang C, Zhang Y. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation. Biomed Pharmacother. 2017;96:1292-1298.

[41] Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. Annu Rev Pathol. 2015;10:173-194.

[42] Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, et al. Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE mice by activating autophagy and reducing ER stress and apoptosis. Int J Mol Sci. 2021;22:818.

[43] Lebeaupin C, Vallée D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018;694:927-947.

[44] Xu H, Tian Y, Tang D, et al. An endoplasmic reticulum stress-MicroRNA-26a feedback circuit in NAFLD. Hepatology. 2021;734:1327-1345.

[45] Du X, Cai C, Yao J, et al. Histone modifications in FASN modulated by sterol regulatory element-binding protein 1c and carbohydrate responsive-element binding protein under insulin stimulation are related to NAFLD. Biochem Biophys Res Commun. 2017;4831:409-417.

[46] Hu Y, He W, Huang Y, et al. Fatty acid synthase-suppressor screening identifies sorting nexin 8 as a therapeutic target for NAFLD. Hepatology. 2021;745:2508-2525.

[47] Jeong S-H, Kim H-B, Kim M-C, et al. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer. J Clin Invest. 2018;1283:1010-1025.

[48] Chi Y, Gong Z, Xin H, et al. Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2/AKT pathway. J Transl Med. 2020;181:126.

[49] Stevenson J, Huang EY, Olzmann JA. Endoplasmic reticulum-associated degradation and lipid homeostasis. Annu Rev Nutr. 2016;36:511-542.

[50] Jin M, Wei Y, Yu H, et al. Erythritol improves nonalcoholic fatty liver disease by activating Nrf2 antioxidant capacity. J Agric Food Chem. 2021;6944:13080-13092.

[51] Vig S, Buitinga M, Rondas D, et al. Cytokine-induced translocation of GRP78 to the plasma membrane triggers a pro-apoptotic feedback loop in pancreatic beta cells. Cell Death Dis. 2019;104:309.

[52] Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) –pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;492:197-211.

RIGHTS & PERMISSIONS

2023 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.